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Integrated PERSEVERE and endothelial
biomarker risk model predicts death
and persistent MODS in pediatric
septic shock: a secondary analysis
of a prospective observational study
Mihir R. Atreya1,2*, Natalie Z. Cvijanovich3, Julie C. Fitzgerald4, Scott L. Weiss4, Michael T. Bigham5,
Parag N. Jain6, Adam J. Schwarz7, Riad Lutfi8, Jeffrey Nowak9, Geoffrey L. Allen10, Neal J. Thomas11,
Jocelyn R. Grunwell12, Torrey Baines13, Michael Quasney14, Bereketeab Haileselassie15, Christopher J. Lindsell16,
Matthew N. Alder1,2 and Hector R. Wong1,2

Abstract
Background: Multiple organ dysfunction syndrome (MODS) is a critical driver of sepsis morbidity and mortality in
children. Early identification of those at risk of death and persistent organ dysfunctions is necessary to enrich patients
for future trials of sepsis therapeutics. Here, we sought to integrate endothelial and PERSEVERE biomarkers to estimate
the composite risk of death or organ dysfunctions on day 7 of septic shock.
Methods: We measured endothelial dysfunction markers from day 1 serum among those with existing PERSEVERE
data. TreeNet® classification model was derived incorporating 22 clinical and biological variables to estimate risk.
Based on relative variable importance, a simplified 6-biomarker model was developed thereafter.
Results: Among 502 patients, 49 patients died before day 7 and 124 patients had persistence of MODS on day 7
of septic shock. Area under the receiver operator characteristic curve (AUROC) for the newly derived PERSEVEREnce model to predict death or day 7 MODS was 0.93 (0.91–0.95) with a summary AUROC of 0.80 (0.76–0.84) upon
tenfold cross-validation. The simplified model, based on IL-8, HSP70, ICAM-1, Angpt2/Tie2, Angpt2/Angpt1, and
Thrombomodulin, performed similarly. Interaction between variables—ICAM-1 with IL-8 and Thrombomodulin with
Angpt2/Angpt1—contributed to the models’ predictive capabilities. Model performance varied when estimating
risk of individual organ dysfunctions with AUROCS ranging from 0.91 to 0.97 and 0.68 to 0.89 in training and test sets,
respectively.
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Conclusions: The newly derived PERSEVEREnce biomarker model reliably estimates risk of death or persistent organ
dysfunctions on day 7 of septic shock. If validated, this tool can be used for prognostic enrichment in future pediatric
trials of sepsis therapeutics.
Keywords: Sepsis, Septic shock, Multiple organ dysfunction syndrome, Endothelial dysfunction, Precision medicine,
Biomarkers, Prognostic enrichment
Graphical abstract

Introduction
Septic shock is a major problem among children admitted to pediatric intensive care units (PICU) [1]. Patients
with persistent multiple organ dysfunction syndrome
(MODS) are at highest risk of early [1] and late mortality [2], new medical device acquisition [3], and long-term
neurocognitive impairment [4]. The current standard of
care—antibiotics and intensive care [5]—although appropriate for most patients, may be insufficient for those
with MODS. Early identification of patients who may
benefit from timely institution of targeted sepsis therapeutics remains a challenge.
Clinical and biological heterogeneity among septic
patients has long confounded efforts to develop efficacious therapeutics [6]. Precision medicine approaches
offer potential solutions to sift through this underlying heterogeneity [7]. Prognostic enrichment through
biomarker-based risk stratification may allow for identification of patients at high risk of death or persistent
organ dysfunctions who can be targeted for enrollment

in future clinical trials of sepsis therapeutics. Conversely,
those deemed low risk can receive standard care and not
be subject to potentially harmful therapies [8].
Organ dysfunctions in sepsis are partly driven by
interaction of activated leukocytes with the endothelium, with subsequent dysregulation of cascades of
inflammation and coagulation, and resultant tissue
hypoperfusion [9, 10]. Despite this biological interplay, most studies of prognostic biomarkers in septic
shock have considered the roles of these compartments
separately rather than together. The serum Pediatric
Sepsis Biomarker Risk Model (PERSEVERE), based on
agnostic whole blood and leukocyte gene expression
studies [11, 12], has been prospectively validated to
estimate baseline risk of sepsis mortality [13–15]. More
recently, it has been used to predict sepsis-associated
acute kidney injury and myocardial dysfunction [16,
17], and pediatric acute respiratory distress syndrome
[18]. In parallel, markers of endothelial dysfunction
have been variably correlated with mortality and organ
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dysfunctions in adult [19] and pediatric sepsis [20]. The
prognostic capabilities of the latter to determine clinical outcomes are yet to be validated.
Accordingly, we sought to determine whether integration of markers of endothelial dysfunction and PERSEVERE biomarkers measured on day 1 could reliably
estimate risk of death or persistent organ dysfunctions
on day 7 of septic shock in a large pediatric cohort.

Methods
Study design and patient selection

The study protocol was approved by Institutional Review
Boards of participating institutions [13, 15]. Briefly,
patients under the age of 18 years were recruited from
multiple pediatric ICUs (PICU) across the USA between
2003 and 2019. Inclusion criteria were pediatric-specific
consensus criteria for septic shock [21] and patients
with existing PERSEVERE biomarker data. There were
no study-related interventions except for blood draws.
Clinical and laboratory data were available between day
1 through 7. Patients were followed for 28 days or until
death, whichever came first. Organ dysfunctions were
determined based on modifications to consensus criteria [21] and are detailed in Additional file 1. The primary outcome of interest was a composite that included
patients who died before day 7 or those with ≥ 2 organ
dysfunctions on day 7 of septic shock. We chose this
composite outcome based on the assumption that (1)
non-survivors died due to or with MODS, and that (2)
non-survivors or those with persistence of organ dysfunctions on day 7, despite intensive organ support, represent a subset of patients with a yet unknown biological
predilection that is potentially amenable to therapeutic
intervention. Accordingly, there is sufficient clinical equipoise within this collective of patients to justify efforts
for enrichment in future clinical trials of novel or repurposed sepsis therapeutics. Secondary outcomes were day
7 cardiovascular, respiratory, renal, hepatic, hematologic,
and neurologic dysfunction.
PERSEVERE biomarkers

Concentrations of interleukin 8 (IL-8), heat shock protein 70 kDA (HSP70), C–C chemokine ligand 3 (CCL3),
C–C chemokine ligand 4 (CCL4), granzyme B (GZMB),
interleukin 1 α (IL-1a), and matrix metallopeptidase 8
(MMP8) were previously measured in day 1 serum [13,
15].
Endothelial dysfunction markers

Concentrations of Intercellular adhesion molecule-1
(ICAM-1), Thrombomodulin, Angiopoietin-1 (Angpt1), Angiopoietin-2 (Angpt-2), Tyrosine kinase with
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immunoglobulin-like loops and epidermal growth factor homology domains-2 (Tie-2), Vascular cell adhesion
molecule-1 (VCAM-1), P-selectin, E-selectin, Platelet,
and endothelial cell adhesion molecule-1 (PECAM1) were measured in day 1 serum by Luminex assays
(R&D Systems, MN), according to the manufacturer’s
specifications.
Statistical analyses were performed with Minitab® software (v21.1, PA). Demographic and clinical data were
summarized with percentages or median with interquartile ranges. Differences between groups were determined by chi-square test for categorical variables and
by one-way analysis of variance (ANOVA) for continuous variables. A p value of 0.05 was used to test statistical significance. Twenty-two predictors including clinical
age, serum lactate, PRISM III score [22], and day 1 vasoactive inotropic score (VIS) [23] and biological variables
(ratios of Angpt-2/Tie-2 and Angpt-2/Angpt-1 and Log
(10)-transformed PERSEVERE and endothelial marker
concentrations) were considered. Multiple logistic
regression was used to test the association between individual biomarkers and risk of primary outcome of interest after adjusting for age, sex, and PRISM III score.
Predictive analytics module with automated machine
learning tool was used to discover the best model among
TreeNet®, Random Forests®, Classification and Regression Tree (CART®), and logistic regression models.
TreeNet® consistently provided the least misclassification and was chosen for model derivation. TreeNet®
models, which rely on stochastic gradient boosting, consist of several hundred CART® trees with a limited number of terminal nodes. Iterative steps using recursive data
sampling are used to grow additional trees to explain
residual error from previous trees. While CART® classification only captures interactions of predictor variables
in very specific combinations that influence the outcome
together, TreeNet® allows for the capture of the overall
effect of one predictor variable over another.
Models were weighted to ensure equal sample size
across classes to overcome unequal distribution of
classes of organ dysfunctions in the training dataset.
Second-order interactions between biological variables
were allowed. An event probability threshold of 0.45 was
used to optimize model sensitivity. Tenfold cross-validation was used in test sets. Relative variable importance,
defined as percent improvement with respect to the top
predictor, was used to select variables to develop a simplified model. Test characteristics of risk prediction models
including area under the receiver operator characteristic
curve (AUROC), positive and negative predictive values,
and likelihood ratios were determined. Percent of total
Statistical analyses and modeling
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squared error and % squared error for the top two-way
interactions between biological variables were assessed.
Finally, given the black box nature of TreeNet® models, alternative CART® model was derived to promote
open science and allow for external validation. Briefly,
models were weighted to match sample frequencies and
minimum misclassification cost was chosen to select
the optimal tree. Class probability method and tenfold
cross-validation were used. CART® trees were pruned
to ensure that terminal nodes had > 5% of patients of the
root node.

Results
Baseline characteristics

A total of 502 patients with PERSEVERE and endothelial
marker data were included in this study. Table 1 shows
the demographic data of the cohort by the presence
of death or day 7 MODS. Over one-third of the cohort
(n = 173, 34.5%) patients had the primary outcome of
interest, including 49 patients who died within the first
7 days of septic shock. Patients with death or day 7
MODS had higher day 1 VIS scores, were more likely to
have received steroids, required more organ support, and
had fewer ICU free days. Interrelationship between individual organ dysfunctions is detailed in Additional File
1. Concentrations of individual biomarkers by primary
outcome and multiple logistic regression analyses to test

Table 1 Demographic characteristics and clinical outcomes according to death or day 7 MODS in pediatric septic shock
Variable

No death or day 7 MODS

Death or day 7 MODS

P value

n (%)

329 (65.5%)

173 (34.5%)

Age*

4.2 (1.5, 8.2)

2.7 (0.9, 6.6)

0.007

Sex, M, n (%)

170 (51.6%)

92 (53.2%)

0.748

PRISM III**

10 (6, 15)

15 (9)

< 0.001

Day 1 VIS

10 (2, 21)

20 (5, 50)

< 0.001

Lactate

1.2 (0, 2.3)

1.9 (0.9, 5.1)

< 0.001

Positive blood culture

62 (18.8%)

44 (25.4%)

0.086

Positive culture (any)

174 (52.8%)

108 (62.4%)

0.016

Pulmonary

64 (19.4%)

45 (26.0%)

Extrapulmonary

110 (33.4%)

63 (36.4%)

Gram positive

78 (23.7%)

44 (25.4%)

Gram negative

60 (18.2%)

41 (23.6%)

Viral

22 (6.6%)

13 (7.5%)

Fungal

8 (2.4%)

3 (1.7%)

Source of infection:

0.030

Organism

0.052

Organ dysfunctions on day 7
Max. number of organ failures

0 (0, 1)

2 (1, 3)

< 0.001

Cardiovascular

9

113

< 0.001

Respiratory

38

155

< 0.001

Renal

14

129

< 0.001

Hepatic

6

77

< 0.001

Hematologic

11

96

< 0.001

Neurologic

0

41

< 0.001

Organ support on day 7
Vasoactive support

11 (3.3%)

103 (59.5%)

< 0.001

Mechanical ventilation

46 (13.9%)

158 (91.3%)

< 0.001
< 0.001

Renal replacement therapy

5 (1.5%)

66 (38.5%)

Steroids

158 (48.1%)

101 (58.3%)

28-day Mortality

2 (0.6%)

61 (35.3%)

0.027
< 0.001

PICU LOS days

5 (7)

12 (13)

< 0.001

PICU-free days

23 (7)

15 (16)

< 0.001
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Table 2 Test characteristics of 22-variable TreeNet® PERSEVEREnce
model to estimate risk of death or day 7 MODS in children with
septic shock
Training set

Test set

AUROC

0.93 (0.91–0.95)

0.80 (0.76–0.84)

Weighted misclassification rate

0.16

0.26

True positive, n

150

125

False negative, n

23

48

False positive, n

58

83

True negative, n

271

246

Sensitivity %

86.7 (80.5, 91.2)

72.2 (64.8, 78.6)

Specificity %

82.3 (77.7, 86.2)

74.8 (69.7, 79.3)

Positive predictive value %

72.1 (65.4, 77.9)

60.1 (53.1, 66.7)

Negative predictive value %

92.1 (88.3, 94.9)

83.7 (78.8, 87.6)

Positive likelihood ratio

4.9 (3.9, 6.3)

2.9 (2.3, 3.5)

Negative likelihood ratio

0.2 (0.1, 0.3)

0.4 (0.3, 0.5)

Fig. 1 Area under the receiver operating characteristic (AUROC)
curve for the 22-variable TreeNet® PERSEVEREnce model to estimate
risk of death or day 7 MODS in children with septic shock

their association with death or day 7 MODS, adjusted for
age, sex, and PRISM III score, are detailed in Additional
File 2.
Estimating the risk of death or persistent organ
dysfunctions on day 7 of septic shock

All 22 predictor variables were deemed important
in the TreeNet® classification model. Three hundred
trees were grown, and 220 was considered as the optimal number of trees. Table 2 shows test characteristics of the newly derived PERSEVEREnce model to
estimate risk of death or day 7 MODS. The area under
the receiver operator characteristic curve (AUROC) of
the training set was 0.93 (95% CI 0.91–0.95) and 0.80
(95% CI 0.76–0.84) upon tenfold cross-validation as
shown in Fig. 1. In comparison, summary AUROCs

for clinical, PERSEVERE, and endothelial markers
considered separately were 0.69 (95% CI 0.64–0.74),
0.73 (95% CI 0.68–0.78), and 0.75 (95% CI 0.71–0.79),
respectively. The weighted misclassification rate of the
PERSEVEREnce model was 0.16 and 0.27, and the negative predictive values were 92.1% (95% CI 88.3–94.9)
and 83.7% (95% CI 78.8–87.6) in training and test sets,
respectively. Relative variable importance of predictor
variables and partial dependence plots of individual
predictor variables are shown in Additional File 3. To
test whether early deaths due to septic shock (≤ 48 h)
skewed model performance, we conducted a sensitivity
analysis with exclusion of these patients (n = 27); model
performance was unchanged (data not shown). The test
characteristics of models to estimate risk of individual
organ dysfunctions are shown in Additional File 4. The
AUROCs of organ-specific PERSEVEREnce risk models to predict cardiovascular, respiratory, renal, hepatic,
hematologic, and neurologic dysfunctions on day 7 of
septic shock ranged from 0.91 to 0.96 and 0.68 to 0.89
in test and training sets, respectively, and are shown in
Fig. 2. The relative importance of predictor variables
varied by organ dysfunction, as shown in Additional
File 5.
Interaction between PERSEVERE and endothelial
dysfunction markers consistently contributed to the
prognostic capabilities of the PERSEVEREnce model
to determine the risk of death or day 7 MODS. Interaction between ICAM-1 with IL-8 and thrombomodulin with Angpt-2/Angpt-1 accounted for 7.5 and 2.5%
of total squared error and 13.2 and 10.3% of squared
error, respectively, when estimating risk of death or day
7 MODS. Surface and contour plots of fitted half log
odds of death or day 7 MODS explained by the two-way
interaction of these variables and the top two-way interactions between biological variables in organ-specific
PERSEVEREnce risk models are detailed in Additional
File 6. The top interacting variables and the contribution
of their interactions to the predictive capabilities of the
models varied by organ dysfunction.
Simplified PERSEVEREnce risk models

The top 6 biological variables including two PERSEVERE
biomarkers IL-8 and HSP70 and four endothelial dysfunction markers ICAM-1, thrombomodulin, Angpt-2/
Angpt-1, Angpt-2/Tie-2, selected based on a relative variable importance threshold of > 50% of top predictor, were
used to develop simplified TreeNet® models to estimate
risk of death or persistent organ dysfunctions on day 7
of septic shock. When estimating risk of death or day 7
MODS, 206 trees were considered as the optimal number
of trees. The simplified PERSEVEREnce biomarker model
had an AUROC of 0.89 (0.87–0.92) and 0.78 (0.75–0.83).
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Fig. 2 Area under the receiver operating characteristic (AUROC) curve for the 22-variable TreeNet® organ-specific PERSEVEREnce models to
estimate risk of persistent a cardiovascular, b respiratory, c renal, d, hepatic, e hematologic, and f neurologic dysfunction on day 7 of pediatric septic
shock

The weighted misclassification rate was 0.18 and 0.27 in
training and test sets, respectively. The test characteristics of the simplified model are detailed in Additional File
7. The AUROCs of the simplified organ-specific PERSEVEREnce models to predict cardiovascular, respiratory,
renal, hepatic, hematologic, and neurologic dysfunctions on day 7 of septic shock ranged from 0.84 to 0.97

and 0.66 to 0.88 in training and test sets, respectively. The
corresponding test characteristics are presented in Additional File 8. The top two-way interaction between the 6
variables and their contribution to each risk prediction
model are shown in Additional File 9.
We derived a 7-terminal node PERSEVEREnce
CART® model to estimate risk of death or day 7

Atreya et al. Critical Care

(2022) 26:210

MODS as shown in Additional File 10. Consistent with
TreeNet® models, ICAM-1, IL-8, Angpt-2/Angpt1, and Thrombomodulin influenced classification of
patients and featured high in the tree. There were 1
low-risk terminal node (TN-1, with 10.6% risk), 3 intermediate risk terminal nodes (TN-2, 3, and 5, with 32.7–
52.6% risk), and 3 high-risk terminal nodes (TN-4, 6,
7, with 60.7–89.3% risk of death or day 7 MODS). Of
note, CART® models had significantly higher misclassification −0.65 and 0.84 in training and test sets—in
comparison with TreeNet® models. The AUROC for
CART® PERSEVEREnce model was 0.83 and 0.73 on
tenfold cross-validation (data not shown).
Prognostic enrichment of organ dysfunctions using
PERSEVEREnce risk models

We tested whether simplified TreeNet® PERSEVEREnce
models could result in meaningful enrichment of patients
with death or persistent organ dysfunctions on day 7 of
septic shock within the cohort. On reanalysis of the dataset, the PERSEVEREnce model correctly predicted those
without death or day 7 MODS in 264 patients (true negatives) and incorrectly predicted the outcome of interest in
28 patients (false negatives). These true and false negative
patients would be excluded from trials using PERSEVEREnce-based classification. In an enriched cohort, 69.4% of
subjects would be expected to have death or day 7 MODS
relative to 34.5% without enrichment. Using the PERSEVEREnce MODS model, the respective rates of cardiovascular, respiratory, renal, hepatic, hematologic, and
neurologic dysfunctions in the enriched cohort, relative
to one without enrichment, would be 47.6 vs 24.3%, 62.8
vs 38.4%, 53.8 vs 28.4%, 37.2 vs 16.5%, 43.8 vs 21.3%, and
17.6 vs 8.2%. The percent of patients requiring vasoactive
support, mechanical ventilation, and renal replacement
therapy in enriched vs. unenriched cohorts would be 44.3
vs 22.7%, 65.7 vs 40.7%, and 29.5 vs 14.2%, respectively.
Organ-specific PERSEVEREnce models had comparable
rates of enrichment for cardiovascular, respiratory, and
renal dysfunction. However, enrichment to 59.2%, 59.1%,
and 29.7% could be achieved for hepatic, hematologic,
and neurologic dysfunctions, respectively.

Discussion
We present newly derived PERSEVEREnce biomarker
risk models to reliably estimate the risk of death or persistent organ dysfunctions on day 7 of septic shock in a
large derivation cohort of pediatric septic shock patients.
To the best of our knowledge, this is the first study to
integrate whole blood/leukocyte and endothelial-derived
biomarkers to predict sepsis-associated organ dysfunctions among children. Although 22 clinical and biological
variables were considered during model development, we
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identified 6 variables, based on 7 serum biomarkers (IL8, HSP70, ICAM-1, Thrombomodulin, Angpt-1, Angpt-2,
and Tie-2), which contributed significantly to the predictive capabilities of the risk prediction models developed.
Interaction of IL-8 with ICAM-1 and thrombomodulin with Angpt-2/Angpt-1 contributed to the predictive
capabilities of the PERSEVEREnce model to estimate
risk of MODS. IL-8 and ICAM-1 are secreted by leukocytes and endothelial cells. They are involved in neutrophil adhesion, extravasation, and degranulation and
contribute to endothelial dysfunction in sepsis [10, 24].
Thrombomodulin is expressed by endothelial cells and
inhibits coagulation under normal circumstances [25].
An increase in Angiopoietin-2 relative to Angiopoietin-1,
is thought to result in inhibition of Thrombomodulin and
has been demonstrated to drive a procoagulant phenotype of endothelial cells [26]. Such recapitulation of key
processes central to the pathophysiology of organ dysfunctions through agnostic machine learning algorithms
lends biological plausibility to our risk prediction models. The relative importance of variables and their interactions varied in the organ-specific PERSEVEREnce
models, which may reflect the unique interaction of activated leukocytes with the organotypic endothelium and
highlights the complex biology of organ dysfunctions in
sepsis.
PERSEVERE biomarkers will be used to retrospectively
risk stratify patients and conduct secondary analyses of
the randomized interventional trial of stress hydrocortisone in pediatric septic shock (SHIPPS, NCT03401398).
Small-scale studies have demonstrated correlation
between and feasibility of measuring PERSEVERE
and endothelial markers among pediatric septic shock
patients using MicroKine assays within 20 min [20]. If
prospectively validated, it is conceivable that the PERSEVEREnce risk prediction models developed herein
could be translated to enrich patients for adaptive trials
of repurposed or novel sepsis therapeutics. Based on our
data, a twofold enrichment in death or day 7 MODS, cardiovascular, respiratory, and renal dysfunctions could be
achieved with the PERSEVEREnce biomarker model. The
organ-specific PERSEVEREnce models could be expected
to yield an over threefold enrichment for hepatic, hematologic, and neurological dysfunctions. We surmise that,
because of the high rate of cardiovascular, respiratory,
renal dysfunction, and interventions used to support
these organ systems within the cohort, the respective
organ-specific models did not yield further enrichment
beyond that offered by the model used to estimate risk of
death or day 7 MODS.
The evolution of organ dysfunctions is dynamic [27].
PERSEVEREnce models were developed based on
day 1 biomarkers to predict death or persistent organ
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dysfunction on day 7 with a high negative predictive value
(NPV). It is plausible that biomarkers measured later in
the sepsis course could result in a temporal reclassification of risk. Further, artificial intelligence models based
on clinical and laboratory data have recently shown
promise in identifying patients at risk of MODS in critically ill children with a high positive predictive value [28].
As such these efforts may be viewed as complementary
and, if prospectively validated, could be deployed either
concurrently or sequentially to recalibrate risk of organ
dysfunctions over time.
There are several limitations to our study. (1) 85% of
patients had day 1 MODS in our cohort and only 14%
patients had new and progressive MODS (NPMODS),
the latter defined as those with single organ dysfunction on day 1 who go on to meet MODS criteria or
those with day 1 MODS who accrue at least one additional organ dysfunction between day 1 and 7. In comparison, 58% of patients in the SPROUT study had day
1 MODS with 26% developing NPMODS [1]. We posit
that PERSEVEREnce-based classification would perform equally well or better in a less critically ill cohort,
given the relatively high negative predictive value of the
model. (2) We did not consider phenotypes of pediatric
sepsis MODS such as thrombocytopenia-associated multiorgan failure (TAMOF), immunoparalysis, and sequential MOF (SMOF) [29]. It is therefore likely that there is
substantial heterogeneity within the subset of MODS
patients within our cohort. Future studies may enable
phenotype-specific risk prediction models. (3) Organ
dysfunctions were based on modifications to consensus
criteria established in 2005. Renal dysfunction was based
on updated KDIGO criteria [30]. On the other hand, the
definition of neurological dysfunction was restricted to
those with Glasgow coma scale < 5, fixed dilated pupils,
or the intracranial pressure > 20 mm Hg. The retrospective nature of the study limited our ability to consider
contemporary features, such as neuromuscular weakness and delirium, and highlight the urgent need for
revised criteria for organ dysfunctions in pediatric sepsis
[31]. (4) PERSEVERE serum biomarkers were originally
derived based on gene expression signatures correlated
with 28-day mortality, not MODS, among children with
septic shock. Efforts are currently underway to identify
candidate biomarkers that are correlated specifically with
the MODS signature. (5) The endothelial markers chosen
for this study were based on their putative role in sepsis
pathophysiology and previous association studies [19].
Therefore, it is plausible that other endothelial markers
may further optimize model performance.
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Conclusions
In a large cohort of critically ill children, we integrated
PERSEVERE and endothelial markers to reliably estimate
risk of death or persistent organ dysfunctions on day 7 of
septic shock. If prospectively validated, PERSEVEREnce
biomarkers may facilitate prognostic enrichment of pediatric patients with organ dysfunctions in future pediatric
trials of sepsis therapeutics.
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